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Background: Major histocompatibility complex (MHC)
class I molecules present short peptides generated by
intracellular protein degradation to cytotoxic T lympho-
cytes (CTL). The multisubunit, non-lysosomal pro-
teinases known as proteasomes have been implicated
in the generation of these peptides. Two interferon-y
(IFN-y)-inducible proteasome subunits, LMP2 and
LMP7, are encoded within the MHC gene cluster in a
region associated with antigen presentation. The incor-
poration of these LMP subunits into proteasomes may
alter their activity so as to favour the generation of pep-
tides able to bind to MHC class I molecules. It has been
difficult, however, to demonstrate a specific requirement
for LMP2 or LMP7 in the presentation of peptide
epitopes to CTL.
Results: We describe a T-cell lymphoma, termed SP3,
that displays a novel selective defect in MHC class
I-restricted presentation of influenza virus antigens. Of
the MHC-encoded genes implicated in the class I path-
way, only LMP2 is underexpressed in SP3 cells. Expres-
sion of IFN--y in transfected SP3 cells simultaneously
restores LMP2 expression and antigen presentation to
CTL. Expression of antisense-LMP2 mRNA in these
IFN-y-transfected cells selectively represses antigen
recognition and the induction of surface class I MHC
expression. Moreover, the expression of this antisense-
LMP2 mRNA in L929 fibroblast cells, which constitu-
tively express LMP2 and have no presentation defect,
blocks the presentation of the same influenza virus anti-
gens that SP3 cells are defective in presenting.
Conclusions: Our results show that the LMP2 pro-
teasome subunit can directly influence both MHC class
I-restricted antigen presentation and class I surface
expression.
Current Biology 1995, 5:923-930
Background
The expression of major histocompatibility complex
(MHC) class I molecules is frequently downregulated on
the surface of malignant tumor cells [1]. Because these
molecules present tumor-specific peptides to cytotoxic T
lymphocytes (CTL), their downregulation allows the
tumour cell variants to escape lysis and detection by
CTL, a natural process of immune selection [2]. Crystal-
lographic studies have shown clearly how peptides bind
to class I molecules [3]. In addition, the characterization
of self-peptides eluted from purified class I molecules has
shown that they are usually 8-10 amino acids long, and
that the peptides presented by a particular class I
molecule have certain amino-acid sequence features in
common - these features are known as an allele-specific
motif [4,5].
The peptides presented by class I molecules can be
derived from intracellular pathogens, endogenous self
proteins or tumor-specific proteins, and are transported
from the cytosol into the endoplasmic reticulum, where
they associate with the MHC class I heavy chain and
light chain (32 microglobulin) components [6-8]. Stud-
ies of mutant cell lines with defects in intracellular
antigen presentation associated with low levels of cell-
surface class I expression have demonstrated the crucial
roles of the peptide itself, as well as of the transporters
associated with antigen processing (TAPs), in class I
assembly and cell-surface expression [9-12]. Moreover,
analysis of a functional polymorphism of TAP2 in the
rat, and the development of TAP- and ATP-dependent
in vitro peptide transport assays, have shown that the
TAP1-TAP2 heterodimeric complex is a peptide trans-
porter involved in the delivery of peptides to class I
molecules [13-16].
Less is known about how peptides suitable for binding to
class I molecules are derived from intracellular proteins.
Recently, evidence has accumulated that proteasomes
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functional experiments with mutant cell lines lacking
both LMP2 and LMP7 have provided little evidence for
the involvement of LMP2 and LMP7 in class I-restricted
antigen presentation [38-42], and studies of mutant mice
lacking expression of LMP2 or LMP7 [43,44] have failed
to define precisely the respective functions of these pro-
teasome subunits in the class I antigen-presentation
pathway.
Here, we describe a T-cell lymphoma, known as SP3,
that has a selective, epitope-specific antigen-presentation
defect. The defect is associated with a lack of LMP2
expression but a normal level of cell-surface MHC class I
molecules. Antigen presentation and LMP2 expression
are restored by IFN-y, but the expression of an anti-
sense-LMP2 mRNA prevents this restoration. Moreover,
the expression of this antisense mRNA in L929 fibroblast
cells, which constitutively express LMP2 and have no
presentation defect, reproduces the presentation defect
of SP3 cells. LMP2-containing (LMP2+) proteasomes
are therefore required for the presentation of specific
antigens to CTL.
Fig. 1. Selective recognition of influenza-infected SP3 target cells
by CTL specific for different influenza viral antigens. (a) CTL
clone HA8, specific for residues 354-362 of influenza A/PR/8/34
HA. (b) CTL clone HAl 1, specific for residues 259-266 of
A/PR/8/34 HA. (c) NS1-CTL, specific for residues 152-160 of
A/PR/8/34 NS1. (d) NP-CTL, specific for residues 50-57 of
A/PR/8/34 NP. SP3 cells were infected with A/PR/8/34 () or
control influenza virus strain E61-13-H17 (O), or incubated with
1 mM of the appropriate synthetic peptide epitope () and used
as targets for CTL (at the indicated effector:target ratios) in
chromium-release assays. NP-CTL were also incubated with SP3
cells infected with 10 pfu per cell of the recombinant vaccinia
viruses NP-VAC (A) or control WR-VAC (A).
may generate such peptides. The 20S proteasome [17-19]
is an abundant, non-lysosomal protease that catalyzes the
cleavage of peptide bonds on the carboxy-terminal side
of basic, hydrophobic or acidic amino-acid residues. It
is a cylindrical particle composed of fourteen different
subunits arranged in four stacked rings [20-22], and is
differentially distributed in the cytoplasm, nucleus and
other cellular compartments, depending on the cell type
studied [23-25]. The 20S proteasome forms the core of
a larger 26S protease, which catalyzes the ATP-depen-
dent degradation of ubiquitinated proteins [26,27], and
there is some evidence that ubiquitin-dependent prote-
olysis is involved in the processing of some class I-
restricted antigens [28,29]. In addition, two IFN-y-
inducible genes, designated LMP2 and LMP7, which
exhibit homology to genes encoding proteasome sub-
units, have been found adjacent to the TAP genes within
the MHC gene cluster [30-33].
In vitro proteolysis assays using proteasome fractions
have demonstrated that LMP2 and LMP7 may alter
the preferred cleavage specificity of the proteasome [34,
35]. In addition, purified proteasomes containing these
two proteins are able to generate epitopes from syn-
thetic peptides [36] and intact proteins [37]. However,
Results and discussion
An antigen-presentation defect in SP3 cells
The stable metastatic cell line termed SP3 was generated
by syngeneic in vivo passage of the AKR-mouse-derived
BW5147 T-cell lymphoma (BW-O) [45]. SP3 cells do
not have a significant defect in their cell-surface levels of
the class I molecules H-2Kk and H-2Dk (see Fig. 4).
After infection with the influenza virus strain A/PR/
8/34, however, SP3 cells are inefficiently recognized by
the Kk-restricted influenza hemagglutinin-specific CTL
clones HA8 and HA11 (Fig. la,b). This antigen-presen-
tation defect is not limited to HA, because a Kk-
restricted epitope of the influenza non-structural pro-
tein NS1 is also poorly recognized by specific polyclonal
CTL (NS1-CTL) (Fig. lc). SP3 cells can, however, be
efficiently lysed by CTL clones HA8 and HAll, and
the polyclonal NS1-CTL, in the presence of the appro-
priate peptide (Fig. 1). It is unlikely, therefore, that a
mutation has occurred affecting the Kk heavy chain of
SP3 cells. The lack of recognition is not due to an
aborted infection by the influenza virus, because the
same SP3 cells are efficiently lysed by Kk-restricted,
influenza nucleoprotein (NP)-specific CTL (NP-CTL;
Fig. d). The presentation defect is also observed in SP3
cells infected with a recombinant vaccinia virus express-
ing either a full-length, cytoplasmic form of HA (L-H1-
VAC) or a 70-residue HA fragment (KG34-VAC)
(Table 1).
To identify the step in the class I antigen-presentation
pathway in which SP3 cells are defective, we generated
recombinant vaccinia viruses expressing only the HA8 or
the HA11 peptide epitopes. In contrast to SP3 cells
expressing full-length HA, SP3 cells infected with vac-
cinia viruses expressing these HA peptide epitopes were
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efficiently lysed by HA8 or HA11 CTLs (Table 1). These
results indicate that SP3 cells have a processing defect
which prevents the efficient presentation of some intra-
cellular antigens, but that their ability to transport anti-
genic peptides and peptide-class I complexes is not
impaired. This latter point was confirmed by the finding,
based on northern and western blotting experiments
(data not shown), that SP3 cells express normal levels of
TAP1 and TAP2.
IFN--y restores HA antigen presentation by SP3 cells
IFN--y has been shown to correct class I antigen-pres-
entation defects in other tumor cell lines [46,47]. We
therefore tested the ability of SP3 cells to present antigen
after pre-incubation with IFN-y. Treatment with IFN--y
restored the ability of HA8 and HA11 CTLs to lyse SP3
cells that were infected with a vaccinia virus expressing
full-length HA (Table 1). Similarly, IFN-y-treated SP3
cells infected with KG34-VAC were lysed by HA8
CTLs (Table 1). SP3-IFN-'y cells - stable transfectants
expressing a murine recombinant IFN-y gene [48] -
were also able to process HA (data not shown). Thus,
SP3 cells have a selective defect in the processing of long
polypeptide sequences of HA that is fully reversed by
expressing IFN-y.
SP3 cells are regulatory mutants for LMP2 expression
LMP2 and LMP7 are IFN-'y-inducible proteasome sub-
units proposed to be involved in antigen presentation.
Their expression might, therefore, be altered in SP3 cells.
Immunoprecipitation of SP3 cell lysates with an anti-rat
proteasome antiserum [49] followed by two-dimensional
gel electrophoresis showed that these cells lack the LMP2
subunit, but constitutively express the LMP7 subunit
(Fig. 2a). This phenotype is cell-type specific and not
generally observed in the thymocytes from which SP3
cells are originally derived [25].
SP3 cells are regulatory mutants, because LMP2 mRNA
and protein could both be induced in them by IFN-'y
(Fig. 2b,d and Fig. 3). In addition to inducing LMP2,
IFN-y treatment also led to a dramatic decrease in the
expression of a constitutively expressed proteasome sub-
unit (Fig. 2a,b) - probably the 8 subunit [50]. Thus, as
reported previously [51-53], incorporation of LMP2 and
the presumed subunit into proteosomes was found to
be mutually exclusive and IFN-y-regulated. In contrast,
the level of LMP7 in the proteasome remained constant
relative to the levels of the constitutive subunits and was
unaffected by IFN-y treatment. A parallel analysis of
precipitates obtained using.an anti-LMP antiserum (anti-
H-2d allo-antiserum) [54] showed that IFN-y generated
a specific LMP2+ proteasome subset in SP3 cells that
could not be precipitated in the absence of LMP2
(Fig. 2c,d; [55]).
LMP2+ proteasomes are required for presentation of
HA to CTL
In order to test whether the HA presentation defect was
due solely to a lack of LMP2, we used different vectors to
express LMP2 in SP3 cells. However, transfection of these
cells with the LMP2 gene did not allow them to produce
LMP2+ proteasomes, even though LMP2 mRNA and
unprocessed LMP2 protein could be detected in the
transfected cells. A similar failure of LMP2 mutant cells to
incorporate expressed LMP2 into proteasomes has been
reported previously [42]. It is possible, therefore, that
additional components required for post-translational
processing events that are essential in proteasome assembly
are absent in SP3 cells but are induced by IFN-y.
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Fig. 2. Modulation by IFN-y of the proteasome subunit composition in SP3 cells. Two-dimensional gel electrophoresis of proteasomes
from untreated (a,c) or IFN-y-treated (b,d) SP3 cells. Lysates were immunoprecipitated with an anti-rat-proteasome antiserum (a,b) or
an anti-H-2d allo-antiserum (anti-LMP) (c,d). The position of actin (act) is indicated for reference. Circles indicate the location of
processed LMP2 (present in (b) and (d); molecular weight 21 kDa, isoelectric point of 4.7) and LMP7 (present in (a),(b) and (d),
molecular weight 24 kDa, isoelectric point of 7.5). The long arrows indicate the presumed 8 proteasome subunit.
In order to investigate whether the LMP2 subunit was
directly involved in HA presentation, we suppressed
LMP2 expression in the SP3-IFN-,y cells by use of an
antisense-LMP2 mRNA. A full-length cDNA encoding
H-2k LMP2 was cloned in reverse orientation into the
expression plasmid pREP4, generating pREP4tLMP2;
after electroporation into SP3-IFN-y cells, stable clones
were isolated. As a control, the empty pREP4 vector was
introduced into SP3 and SP3-IFN-y cells. Unexpectedly,
the double-transfected clones (SP3-IFN-'y-otLMP2 cells)
exhibited a significant decrease in the levels of cell-surface
class I molecules compared to SP3-IFN-y cells (Fig. 4),
Fig. 3. Effects of IFN-y on LMP mRNA expression in SP3 cells. Northern hybridization analysis of (a) LMP7 expression and (b) LMP2
expression. Total RNA was isolated from BW-O cells, SP3 cells, AKR mouse splenocytes and SP3 cells pre-incubated with IFN-y.(c) The blotted gel after staining with ethidium bromide.
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Fig. 4. Reduction of surface class I MHC molecules by antisense-
LMP2 mRNA in SP3-IFN-y cells. Indirect immunostaining of SP3-
pREP4 cells (black solid line), SP3-IFN--y-pREP4 cells (black
broken line) and SP3-IFN-y-otLMP2 cells (grey solid line) with (a)
antibody 16-3-1 N (ATCC), specific for H-2Kk, and (b) antibody
15-5-5S (ATCC), specific for H-2Dk, followed by staining with
fluorescein isothiocyanate-conjugated goat-anti-mouse immuno-
globulin G. Background staining is represented by the grey
broken line.
whereas the level of class I molecules was unaffected in
cells transfected with the empty pREP4 vector (SP3-
IFN-y-pREP4 cells). The reduction of class I MHC
expression was not due to the loss of IFN-y expression in
SP3-IFN-y-aoLMP2 cells, because the addition of exoge-
nous IFN-y did not restore the expression of surface class
I molecules to normal levels (data not shown).
Immunoprecipitation and western immunoblotting
experiments confirmed that the expression of LMP2 and
LMP2+ proteasomes was suppressed in these clones, but
the total proteasome pool size was unaffected (Fig. 5).
Cytotoxicity assays showed that, in contrast to SP3-IFN-
-y cells, SP3-IFN-y-a0LMP2 cells were completely
unable to present HA to HA8 CTL, whereas NP recog-
nition was preserved. The phenotype of these cells there-
fore mimicked that of the parental SP3 cells (Fig. 6).
These results demonstrate that SP3 cells require LMP2+
proteasomes in order to present HA to CTL efficiently.
There are several possible explanations for the epitope-
selectivity of the antigen-presentation defect in SP3 cells.
Fig. 5. Suppression of LMP2+ proteasomes by antisense-LMP2
mRNA expression. (a) Immunoprecipitation of total proteasome
pools by rabbit anti-rat-proteasome antiserum analyzed by one-
dimensional SDS-PAGE on a 10 % gel. (b) Western immunoblot
analyzing LMP2 expression. Lane 1, SP3 cells; lane 2, SP3 cells
treated with IFN-y; lane 3, SP3-IFN-y-pREP4 cells; lane 4, SP3-
IFN-y-aLMP2 cells. The arrows indicate the location of the
processed form of LMP2. Antisense-LMP2 mRNA does not alter
the overall content of proteasomes, but there is a dramatic
decrease in the LMP2 + proteasome subset in the same precipitates.
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Fig. 6. Cytotoxicity assay showing that antisense-LMP2 mRNA
specifically suppresses HA8 epitope recognition by CTL. Control
SP3-pREP4 cells (O), SP3-IFN--y-pREP4 transfectants () and
SP3-IFN-y-axLMP2 cells () were infected with A/PR/8/34 and
used as targets for (a) HA8 CTL or (b) NP-CTL, at the indicated
effector:target ratios, in a chromium-release assay.
CTL with distinct specificities may have different affini-
ties for antigen, or may be triggered by different levels of
antigen. Different affinities of different epitopes for the
Kk class I molecule is unlikely to be the explanation, as
the efficiently presented NP epitope has a lower binding
affinity than the poorly presented HA epitopes [56]. It is
possible that the NP epitope is much more efficiently
processed from the intact protein than are HA epitopes,
because the NP epitope is immunodominant in the poly-
conal CTL response to influenza virus. Variations in the
intracellular locations of protein antigens might also affect
their processing.
In order to confirm the critical role of LMP2 in the gen-
eration of HA epitopes, H-2k L929 fibroblast cells,
which efficiently present HA to CTL [57], were trans-
fected with pREP4oaLMP2. Stable transfectants were
isolated as a polyclonal population and used as targets
in cytotoxicity assays; HA8 and NP CTLs were used
as effectors. Constitutive levels of cell-surface class I
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Fig. 7. Cytotoxicity assay testing the effect of antisense-LMP2
mRNA on L929 cells. L929 cells (O) or L929 cells transfected
with pREP4aLMP2 () were infected with A/PR/8/34 and used
as targets for (a) HA8 CTL or (b) NP-CTL, at the indicated
effector:target ratios, in a chromium-release assay.
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molecules were not decreased in cells expressing anti-
sense-LMP2 mRNA (data not shown). When these cells
were infected with influenza virus, however, they
showed a clear block in presentation of the HA8 epi-
tope, in comparison with the parental L929 cells; in
contrast, presentation of the NP epitope was unaffected
(Fig. 7). Similar results were obtained in three experi-
ments, and have also been confirmed in assays using
clones derived by limiting dilution from the polyclonal
population of L929 transfectants expressing antisense-
LMP2 mRNA. Moreover, infection of these L929-
aLMP2 cells with the recombinant vaccinia virus
expressing the minimal HA8 epitope permitted their
efficient lysis by HA8 CTL (data not shown). Therefore,
the phenotype of L929 cells expressing antisense-LMP2
mRNA mimics that of SP3 cells. Our results are consis-
tent with the hypothesis that the LMP2 proteasome sub-
unit has proteolytic activity [58], and that this activity is
required for the generation of some epitopes recognized
by CTL.
Conclusions
Our results provide clear evidence for the involvement
of LMP2, not only in antigen presentation, but also in
the upregulation of class I expression. Because neither
the absence of LMP2 nor the presence of antisense-
LMP2 mRNA alter the constitutive level of class I mol-
ecules on the surface of SP3 cells, it appears that, upon
IFN-y induction, LMP2 specifically controls the supply
of peptide by forming novel 'immune' LMP2+ protea-
somes that also contain LMP7 and other constitutively
expressed subunits. Thus, although the SP3 (LMP2-7+ )
proteasomes supply sufficient peptides to maintain the
basal level of class I molecules, the repertoire of peptides
generated is deficient for the presentation of some viral
antigens and for inducing tumor rejection [48].
Our results may therefore explain why LMP2 mutant
animals have normal constitutive levels of MHC class I
molecule expression, but nevertheless have a significant
deficiency in their CD8+ T-cell repertoire [43]. If the
repertoire is dependent on maximal peptide diversity,
associated with a completely efficient class I antigen-
presentation capacity, then the absence of LMP2 would
result in reduced CD8+ T-cell diversity. Our results fur-
ther suggest that the reduction in the basal level of
expression of surface class I molecules observed in LMP7
knock-out mice [44] is due to the fact that LMP7 is a
component of both constitutive and 'immune' LMP2+
proteasomes.
The antisense approach we have employed has proved to
be a useful tool in dissociating the specific functions of
LMP2 from the pleiotropic effects mediated by IFN-y. It
should be possible to use this approach to study other
proteasome subunits, for which natural mutants are not
yet available, and to provide a source of various types of
proteasomes for use in in vitro assays.
Materials and methods
Cell lines
The original BW-O cell line was derived from the non-
metastatic BW5147 T-cell lymphoma (H-2k, AKR/J mouse
origin, Salk Institute, California). It gave rise to the SP3
metastatic variant upon successive syngeneic in vivo passages
[45]. The H-2k L929 fibroblast cell line has been well docu-
mented. Cells were cultured in RPMI 1640 or DMEM
medium supplemented with 10 % fetal calf serum (FCS;
Gibco). For treatment with IFN-y, cells were incubated for
48 h with 500 U ml-' mouse recombinant IFN-y (Holland
Biotechnology).
CTL and synthetic peptides
The CTL used in these experiments are Kk-restricted, and have
been described previously. The polyclonal NP-specific CTL
recognize amino-acid residues 50-57 of A/PR/8/34 NP
[57,59]. The polyclonal NS1-specific CTL recognize amino-
acid residues 152-160 of A/PR/8/34 NS1 [60]. CTL clones
HA11 and HA8 recognize amino-acid residues 259-266 and
354-362, respectively, of A/PR/8/34 HA [57]. The CTL
were restimulated weekly with peptide-treated syngeneic
spleen cells and human recombinant IL-2 (20 Cetus U ml-l).
Peptides were synthesized and purified by standard methods.
Cytotoxicity assays were performed using a standard [51Cr]-
release assay [61].
Influenza and recombinant vaccinia viruses
Influenza virus strains A/PR/8/34 (Mount Sinai strain) and
E61-13-H17 [62] were used for infection in the cytotoxicity
assays. Recombinant vaccinia viruses were generated by stan-
dard methods, and were expressed from the P7.5 vaccinia pro-
moter. L-H1-VAC [63], KG34-VAC [57] and NP-VAC [64]
have been described previously. HA259-266-VAC and HA354-
362-VAC express the peptide epitopes recognized by CTL
clones HA11 and HA8, respectively, and were generated as
described [65].
Northern blots
Total RNA extraction, electrophoresis, blotting on to
Hybond-N nylon membrane and hybridization were carried
out according to standard protocols [66]. Each lane was loaded
with 30 ,ug RNA. DNA probes were labeled by random prim-
ing (Boehringer kit) using [ 32 p]dATP (Amersham). The
TAP1 probe consisted of the 1.45 kb and 1.25 kb EcoRI frag-
ments isolated from the plasmid pHbApr-l-neo-510-15 (con-
taining the full-length rat TAP1 cDNA) [39,67]. The TAP2
probe comprized the 0.9 kb EcoRI fragment from plasmid
pEII-4 (containing the mouse TAP2 genomic sequence) [68].
For LMP2 mRNA detection, we used a 0.8 kb EcoRI-Sall
fragment isolated from the plasmid pcDNAneol-W10 (con-
taining the full length cDNA of H-2d LMP2) [30], and for
LMP7 mRNA detection, we used a 0.9 kb EcoRI fragment
isolated from plasmid W14-4 (containing H-2d LMP7 cDNA
sequences (J. Monaco, unpublished data)).
Western blots
Total cell lysate preparation, electrophoresis and transfer onto
nitrocellulose were carried out according to standard proce-
dures [66]. TAP1 and TAP2 were detected using rabbit antis-
era raised against synthetic peptides corresponding to the
carboxyl terminus of the respective rat TAP polypeptides, as
described [39,69]. LMP2 was detected using a rabbit polyclonal
antiserum directed against recombinant rat LMP2 (S.T. and
A.J.R., unpublished data). Following incubation with 500-fold
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diluted horseradish peroxidase-conjugated donkey anti-rabbit
immunoglobulin G (Amersham), blots were developed using
an enhanced chemiluminescence kit (Amersham).
Metabolic radiolabeling and immunoprecipitation
Cells (107) were incubated for 1 h in RPMI 1640 medium
lacking cysteine and methionine (Gibco) and containing 10 %
FCS at 37°C in an atmosphere of 7 % CO 2 in air. Following
incubation, a mixture of [35S]methionine and [35S]cysteine
(Translabel, ICN Radiochemicals, California) was added to a
final specific activity of 200 RtCi ml-1 and the cells were incu-
bated for a further 5 h under the same conditions. Subse-
quently, cell lysates were prepared as described previously [70],
except that no peptide was added to the extracts. For analysis
by two-dimensional gel electrophoresis, 300 pl of each lysate,
prepared from untreated or IFN-y-treated SP3 cells, was
divided into two aliquots and incubated on ice for h with
either 15 .Ll of a rabbit anti-proteasome antiserum [49] or
30 l1 of an anti-H-2d (BALB/b anti-BALB/c) allo-antiserum
[54]. Following incubation, 100 .1 of a 10 % suspension of
protein A-Sepharose CL-4B (Pharmacia) was added to each
sample. After a 1 h incubation at 4 C, the beads were washed
and resuspended in sample buffer (pH 9.5) containing 9 M
urea, 4 % Nonidet-P40, 2 % 2-mercaptoethanol and 2 % 9-11
ampholytes (Ampholines, LKB Instruments, Maryland) [71].
Two-dimensional gel electrophoresis
The samples prepared as described above were analysed by high
resolution two-dimensional electrophoresis [71]. The first-
dimension isoelectric focusing gels contained isoelectric point
3.5-10 resolyte (BDH), and the second-dimension slab gels
were 8-18 % linear polyacrylamide gradients. Carbamylated
rabbit muscle creatine phosphokinase (EC 2.7.3.2, Sigma) was
used as an internal standard for each isoelectric focusing gel, and
Rainbow protein molecular weight markers (Amersham) were
used as standards for the second-dimension gels. Gels were
fixed, dried and subjected to autoradiography for 2-3 weeks.
LMP2 antisense mRNA expression plasmid
A full-length LMP2 cDNA was isolated by RT-PCR using
mRNA purified from L929 cells and the oligonucleotides
5'-CCGAGCCCCGCTCTGCTGAGA-3' and 5'-GGAAG-
GGACTTCTGGGGATCAG-3'. After verification of its
sequence, the cDNA was inserted in reverse orientation into
the expression vector pREP4 (Invitrogen) to give plasmid
pREP4otLMP2. This plasmid was introduced into SP3 cells by
electroporation, and into L929 cells as a calcium phosphate
precipitate. Transfectants were selected with 2 mg ml-1 and
0.75 mg ml-1 hygromycin B, respectively.
Acknowledgements: We thank J. Monaco for providing mouse
LMP2 and LMP7 plasmids, the Cetus Corporation for recombi-
nant human IL-2, S. Reed for generating the HA354-362-VAC
and HA259-266-VAC viruses, E. Vercauteren for technical help,
and G. G. Brownlee for support. C.S. was funded by an ASLK
grant and K.G. by the Wellcome Trust and the E. P. Abraham
Research Fund.
References
1. Festenstein H, Schmidt W: Variation in MHC antigenic profiles of
tumor cells and its biological effects. Immunol Rev 1981, 60:85-127.
2. Finn OJ: Tumor-rejection antigens recognized by T lymphocytes.
Curr Opin Immunol 1993, 5:701-708.
3. Young ACM, Nathenson SG, Sacchettini JC: Structural studies of
class I major histocompatibility complex proteins: insights into
antigen presentation. FASEB J 1995, 9:26-36.
4. R6tzschke 0, Falk K, Deres K, Schild H, Norda M, Metzger J, et a.:
Isolation and analysis of naturally processed viral peptides as
recognized by cytotoxic T cells. Nature 1990, 348:252-254.
5. Van Bleek GM, Nathenson SG: Isolation of an endogenously
processed immunodominant viral peptide from the class I H-2Kb
molecule. Nature 1990, 348:213-216.
6. Yewdell JW, Bennink JR: Brefeldin A specifically inhibits presenta-
tion of protein antigens to cytotoxic T ymphocytes. Science 1989,
244:1072-1075.
7. Nuchtern JG, Bonifacino JS, Biddison WE, Klausner RD: Brefeldin A
implicates egress from the endoplasmic reticulum in class I-
restricted antigen presentation. Nature 1989, 339:223-226.
8. Lapham CK, Bacik I, Yewdell JW, Kane KP, Bennink JR: Class I mol-
ecules retained in the endoplasmic reticulum bind antigenic pep-
tides. J Exp Med 1993, 177:1633-1641.
9. Monaco JJ: A molecular model of MHC class-l-restricted antigen
processing. Immunol Today 1992, 13:173-179.
10. Demars R, Spies T: New genes in the MHC that encode proteins for
antigen processing. Trends Cell Biol 1992, 2:81-86.
11. Townsend A, Trowsdale J: The transporters associated with antigen
presentation. Semin Cell Biol 1993, 4:53-61.
12. Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S: TAPI
mutant mice are deficient in antigen presentation, surface class I
molecules, and CD4-8* T cells. Cell 1992, 71:1205-1214.
13. Powis SJ, Deverson EV, Coadwell WJ, Ciruela A, Huskisson NS,
Smith H, et a.: Effect of polymorphism of an MHC-linked trans-
porter on the peptides assembled in a class I molecule. Nature
1992, 357:211-215.
14. Neefjes JJ, Momburg F, HAmmerling GJ: Selective and ATP-depen-
dent translocation of peptides by the MHC-encoded transporter.
Science 1993, 261:769-771.
15. Schumacher TNM, Kantesaria DV, Heemels M-T, Ashton-Rickardt
PG, Shepherd JC, FrOh K, et a/.: Peptide length and sequence
specificity of the mouse TAP1/TAP2 translocator. Exp Med 1994,
179:533-540.
16. Momburg F, Roelse J, Howard JC, Butcher GW, Hammerling GJ,
Neefjes JJ: Selectivity of MHC-encoded peptide transporters from
human, mouse and rat. Nature 1994, 367:648-651.
17. Orlowski M: The multicatalytic proteinase complex, a major
extralysosomal proteolytic system. Biochemistry 1990, 29:
10289-10297.
18. Rivett AJ: Proteasomes: multicatalytic proteinase complexes.
Biochem J 1993, 291:1-10.
19. Goldberg AL, Rock KL: Proteolysis, proteasomes and antigen
presentation. Nature 1992, 357:375-379.
20. Baumeister W, Dahlmann B, Hegerl R, Kopp F, Kuehn L, Pfeifer G:
Electron microscopy and image analysis of the multicatalytic
proteinase. FEBS Lett 1988, 241:239-245.
21. Djaballah H, Rowe AJ, Harding SE, Rivett AJ: The multicatalytic
proteinase complex (proteasome): structure and conformational
changes associated with changes in proteolytic activity. Biochemrn J
1993, 292:857-862.
22. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R: Crystal
structure of the 20S proteasome from the Archaeon T. acidophilum
at 3.4 A resolution. Science 1995, 268:533-539.
23. Rivett AJ, Knecht E: Proteasome location. Curr Biol 1993, 3:
127-129.
24. Tanaka K, Tamura T, Yoshimura T, Ichihara A: Proteasomes: protein
and gene structures. New Biol 1992, 4:173-187.
25. Frentzel S, Kuhn-Hartmann I, Gernold M, Gott P, Seelig A, Kloetzel
P-M: The major-histocompatibility-complex-encoded -type pro-
teasome subunits LMP2 and LMP7. Eur J Biochem 1993, 216:
119-126.
26. Eytan E, Ganoth D, Armon T, Hershko A: ATP-dependent incorpora-
tion of 20S protease into the 26S complex that degrades proteins
conjugated to ubiquitin. Proc Natl Acad Sci USA 1989, 86:
7751-7755.
27. Driscoll J, Goldberg AL: The proteasome (multicatalytic protease)
is a component of the 1500-kDa proteolytic complex which
degrades ubiquitin-conjugated proteins. J Biol Chem 1990, 265:
4789-4792.
28. Townsend A, Bastin J, Gould K, Brownlee G, Andrew M, Coupar B,
et al.: Defective presentation to class I-restricted cytotoxic T lym-
phocytes in vaccinia-infected cells is overcome by enhanced degra-
dation of antigen. Exp Med 1988, 168:1211-1224.
29. Michalek MT, Grant EP, Gramm C, Goldberg AL, Rock KL: A role
for the ubiquitin-dependent proteolytic pathway in MHC class I-
restricted antigen presentation. Nature 1993, 363:552-554.
30. Martinez CK, Monaco JJ: Homology of proteasome subunits to a
major histocompatibility complex-linked LMP gene. Nature 1991,
353:664-667.
930 Current Biology 1995, Vol 5 No 8
31. Frentzel S, Graf U, Hmmerling GJ, Kloetzel P-M: Isolation and
characterization of the MHC linked -type proteasome subunit
MC13 cDNA. FEBS Lett 1992, 302:121-125.
32. Glynne R, Powis SH, Beck S, Kelly A, Kerr L-A, Trowsdale J: A pro-
teasome-related gene between the two ABC transporter loci in the
class II region of the human MHC. Nature 1991, 353:357-360.
33. Kelly A, Powis SH, Glynne R, Radley E, Beck S, Trowsdale J: Second
proteasome-related gene in the human MHC class II region. Nature
1991, 353:667-668.
34. Driscoll J, Brown MG, Finley D, Monaco JJ: MHC-linked LMP gene
products specifically alter peptidase activities of the proteasome.
Nature 1993, 365:262-264.
35. Gaczynska M, Rock KL, Goldberg AL: y-interferon and expression
of MHC genes regulate peptide hydrolysis by proteasomes. Nature
1993, 365:264-267.
36. Niedermann G, Butz S, Ihlenfeldt HG, Grimm R, Lucchiari M,
Hoschutzky H, et al.: Contribution of proteasome-mediated pro-
teolysis to the hierarchy of epitopes presented by major histo-
compatibility complex class I molecules. Immunity 1995, 2:
289-299.
37. Dick LR, Aldrich C, Jameson SC, Moomaw CR, Pramanik BC, Doyle
CK, et al.: Proteolytic processing of ovalbumin and 0-galactosidase
by the proteasome to yield antigenic peptides. J Immunol 1994,
152:3884-3894.
38. Arnold D, Driscoll J, Androlewicz M, Hughes E, Cresswell P, Spies
T: Proteasome subunits encoded in the MHC are not generally
required for the processing of peptides bound by MHC class I mol-
ecules. Nature 1992, 360:171-174.
39. Momburg F, Ortiz-Navarette V, Neefjes J, Goulmy E, van de Wal Y,
Spits H, et al.: Proteasome subunits encoded by the major histo-
compatibility complex are not essential for antigen presentation.
Nature 1992, 360:174-177.
40. Yewdell J, Lapham C, Bacik I, Spies T, Bennink J: MHC-encoded
proteasome subunits LMP2 and LMP7 are not required for efficient
antigen presentation. Immunol 1994, 152:1163-1170.
41. Zhou X, Momburg F, Liu T, Motal UMA, Jondal M, Hammerling GJ,
et al.: Presentation of viral antigens restricted by H-2Kb, Db or Kd in
proteasome subunit LMP2- and LMP7-deficient cells. EurJ Immunol
1994, 24:1863-1868.
42. Cerundolo V, Kelly A, Elliott T, Trowsdale J, Townsend A: Genes
encoded in the major histocompatibility complex affecting the gen-
eration of peptides for TAP transport. Eur Immunol 1995,
25:554-562.
43. Van Kaer L, Ashton-Rickardt PG, Eichelberger M, Gaczynska M,
Nagashima K, Rock KL, et al.: Altered peptidase and viral-specific T
cell response in LMP2 mutant mice. Immunity 1994, 1:533-541.
44. Fehling HJ, Swat W, Laplace C, Khn R, Rajewsky K, Muller U, et
al.: MHC class I expression in mice lacking the proteasome subunit
LMP-7. Science 1994, 265:1234-1237.
45. Vanden Driessche T, Verschueren H, De Baetselier P: Association
between MHC class I antigen expression and malignancy of murine
T lymphoma variants. Invasion Metastasis 1990, 10:65-85.
46. Sibille C, Gould K, Hammerling G, Townsend A: A defect in the
presentation of intracellular viral antigens is restored by
interferon--y in cell lines with impaired major histocompatibility
complex class I assembly. Eurl Immunol 1992, 22:433-440.
47. Restifo NP, Spiess PJ, Karp SE, Mule JJ, Rosenberg SA: A nonim-
munogenic sarcoma transduced with the cDNA for interferon y
elicits CD8 + T cells against the wild-type tumor: correlation with
antigen presentation capability. J Exp Med 1992, 175:1423-1431.
48. Raes G, Geldhof A, Vandendriessche T, Opdenakker G, Sibille C,
De Baetselier P: Immunogenization of a murine T-cell lymphoma
via transfection with interferon-gamma. Leukemia 1995, in press.
49. Rivett AJ, Sweeney ST: Properties of subunits of the multicatalytic
proteinase complex revealed by the use of subunit-specific antibod-
ies. Biochem 1991, 278:171-177.
50. Frdh K, Gossen M, Wang K, Bujard H, Peterson PA, Yang Y: Dis-
placement of housekeeping proteasome subunits by MHC-encoded
LMPs: a newly discovered mechanism for modulating the multicat-
alytic proteinase complex. EMBOJ 1994, 13:3236-3244.
51. Akiyama K, Kagawa S, Tamura T, Shimbara N, Takashina M, Kris-
tensen P, et al.: Replacement of proteasome subunits X and Y by
LMP7 and LMP2 induced by interferon-y for acquirement of the
functional diversity responsible for antigen processing. FEBS Lett
1994, 343:85-88.
52. Akiyama K, Yokota K, Kagawa S, Shimbara N, Tamura T, Akioka H,
et a/.: cDNA cloning and interferon y down-regulation of protea-
somal subunits X and Y. Science 1994, 265:1231-1234.
53. Belich MP, Glynne RJ, Senger G, Sheer D, Trowsdale J: Proteasome
components with reciprocal expression to that of the MHC-
encoded LMP proteins. Curr Biol 1994, 4:769-776.
54. Brown MG, Driscoll I, Monaco JJ: Structural and serological similar-
ity of MHC-linked LMP and proteasome (multicatalytic proteinase)
complexes. Nature 1991, 353:355-357.
55. Brown MG, Driscoll , Monaco JJ: MHC-linked low-molecular mass
polypeptide subunits define distinct subsets of proteasomes.
J Immunol 1993, 151:1193-1204.
56. Brown EL, Wooters JL, Ferenz CR, O'Brien CM, Hewick RM, Her-
rmann SH: Characterization of peptide binding to the murine MHC
class I H-2Kk molecule - sequencing of the bound peptides and
direct binding of synthetic peptides to isolated class I molecules.
J Immunol 1994, 153:3079-3092.
57. Gould KG, Scotney H, Brownlee GG: Characterization of two dis-
tinct major histocompatibility complex class I Kk-restricted T-cell
epitopes within the influenza A/PR/8/34 virus hemagglutinin.
I Virol 1991, 65:5401-5409.
58. SeemUller E, Lupas A, Stock D, Lwe J, Huber R, Baumeister W: Pro-
teasome from Thermoplasma acidophilum: a threonine protease.
Science 1995, 268:579-582.
59. Bastin J, Rothbard J, Davey J, Jones I, Townsend A: Use of synthetic
peptides of influenza nucleoprotein to define epitopes recognized
by class I-restricted cytotoxic T lymphocytes. Exp Med 1987,
165:1508-1523.
60. Cossins J, Gould KG, Smith M, Driscoll P, Brownlee GG: Precise
prediction of a Kk-restricted cytotoxic T cell epitope within the NS1
protein of influenza virus using an MHC allele-specific motif.
Virology 1993, 193:289-295.
61. Townsend ARM, Gotch FM, Davey J: Cytotoxic T cells recognize
fragments of the influenza nucleoprotein. Cell 1985, 42:457-467.
62. Lubeck MD, Palese P, Schulman JL: Nonrandom association of
parental genes in influenza A virus recombinants. Virology 1979,
95:269-274.
63. Townsend ARM, Bastin J, Gould K, Brownlee GG: Cytotoxic T lym-
phocytes recognize influenza haemagglutinin that lacks a signal
sequence. Nature 1986, 324:575-577.
64. Smith GL, Levin JZ, Palese P, Moss B: Synthesis and cellular loca-
tion of the ten influenza polypeptides individually expressed by
recombinant vaccinia viruses. Virology 1987, 160:336-345.
65. Gould K, Cossins J, Bastin J, Brownlee GG, Townsend A: A 15
amino acid fragment of influenza nucleoprotein synthesized in the
cytoplasm is presented to class I-restricted cytotoxic T lympho-
cytes. J Exp Med 1989, 170:1051-1056.
66. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: a Laboratory
Manual, 2nd edn. Cold Spring Harbor, New York: Cold Spring Har-
bor Laboratory Press; 1989.
67. Deverson EV, Gow IR, Coadwell WJ, Monaco JJ, Butcher GW,
Howard JC: MHC class II region encoding proteins related to the
multidrug resistance family of transmembrane transporters. Nature
1990, 348:738-741.
68. Cho S, Attaya M, Brown MG, Monaco JJ: A cluster of transcribed
sequences between the Pb and Ob genes of the murine major histo-
compatibility complex. Proc Natl Acad Sci USA 1991,
88:5197-5201.
69. Powis SJ, Townsend ARM, Deverson EV, Bastin J, Butcher GW,
Howard JC: Restoration of antigen presentation to the mutant cell line
RMA-S by an MHC-linked transporter. Nature 1991, 354:528-531.
70. Townsend A, Elliott T, Cerundolo V, Foster L, Barber B, Tse A:
Assembly of MHC class I molecules analyzed in vitro. Cell 1990,
62:285-295.
71. Willard-Gallo KE, Houck DW, Loken MR: Analysis of human lym-
phocyte protein expression I. Identification of subpopulation mark-
ers by two-dimensional polyacrylamide gel electrophoresis. Eur 
Immunol 1988, 18:1453-1461.
Received: 15 May 1995; revised: 20 June 1995
Accepted: 22 June 1995.
